Scribe Therapeutics (NASDAQ:SCTX) Issues Earnings Results

Scribe Therapeutics (NASDAQ:SCTX) issued its earnings results on Wednesday. The company reported ($3.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.20) by $2.36, Zacks reports.

Scribe Therapeutics Price Performance

Shares of NASDAQ:SCTX traded up $1.90 during trading on Wednesday, hitting $30.90. 278,607 shares of the stock were exchanged, compared to its average volume of 232,297. Scribe Therapeutics has a 1-year low of $17.31 and a 1-year high of $39.60.

Analyst Ratings Changes

SCTX has been the topic of a number of research reports. Wells Fargo & Company started coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price objective on the stock. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 target price for the company. Leerink Partners initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price for the company. Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research note on Saturday, August 1st. Finally, Guggenheim began coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Scribe Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $51.75.

Key Headlines Impacting Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $60 price target, implying considerable upside from recent trading levels. The firm’s coverage provides a new bullish valuation reference for the clinical-stage biotechnology company. HC Wainwright Begins Coverage on Scribe Therapeutics
• Positive Sentiment: HC Wainwright expects Scribe’s quarterly losses to narrow after the second quarter of 2026, forecasting EPS of negative $1.02 in Q3 2026 and negative $1.05 in Q4 2026, compared with negative $6.20 in Q2 2026. The firm projects a negative $4.90 EPS loss for fiscal 2027, better than its negative $6.72 forecast for fiscal 2026.
• Neutral Sentiment: Management will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference. These events could provide updates on Scribe’s in vivo CRISPR pipeline, but no new clinical, regulatory, or financial data was announced. Scribe Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Despite the bullish rating, HC Wainwright still forecasts sizable losses across every listed period, including negative $1.10 to negative $1.36 EPS in the first four quarters of 2027. Continued losses and the absence of reported clinical or partnership developments remain risks for SCTX investors.

Insider Transactions at Scribe Therapeutics

In other Scribe Therapeutics news, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the stock in a transaction on Monday, July 27th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the acquisition, the insider directly owned 2,385,075 shares of the company’s stock, valued at $35,776,125. This represents a 16.25% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Carl L. Gordon bought 1,000,000 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the transaction, the director owned 1,348,825 shares in the company, valued at $20,232,375. This represents a 286.68% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 3,727,237 shares of company stock valued at $56,291,746.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.